Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier:
NCT01106469
First received: April 15, 2010
Last updated: April 7, 2014
Last verified: April 2014
  Purpose

The purpose of this study is to investigate the safety, tolerability, food effect as well as the pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and how it is removed from the body over time) and pharmacodynamics (the effects of the drug) of single and multiple ascending doses of JNJ-41443532 in healthy male participants.


Condition Intervention Phase
Healthy
Drug: JNJ-41443532
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male Subjects

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • Determine the pharmacokinetic properties of single and multiple doses JNJ-41443532 as determined by blood level concentrations. [ Time Frame: Part 1 - Approximately 13 weeks; Part 2 - Approximately 7 weeks; Part 3 - Approximately 6 weeks; Part 4 - Approximately 7 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine the safety and tolerability of JNJ-41443532 as determined by evaluation of adverse events, lab results, cardiac monitoring, vital signs, and physical exams. [ Time Frame: Part 1 - Approximately 13 weeks; Part 2 - Approximately 7 weeks; Part 3 - Approximately 6 weeks; Part 4 - Approximately 7 weeks ] [ Designated as safety issue: No ]
  • To explore the relationship between JNJ-41443532 plasma concentrations and pharmacodynamic effects (concentration-effect relationships). [ Time Frame: Part 1 - Approximately 13 weeks; Part 2 - Approximately 7 weeks; Part 3 - Approximately 6 weeks; Part 4 - Approximately 7 weeks ] [ Designated as safety issue: No ]
  • To explore the pharmacodynamic (PD) effects of JNJ-41443532 and to compare the differences between treatment groups [ Time Frame: Part 1 - Approximately 13 weeks; Part 2 - Approximately 7 weeks; Part 3 - Approximately 6 weeks; Part 4 - Approximately 7 weeks ] [ Designated as safety issue: No ]

Enrollment: 74
Study Start Date: February 2010
Study Completion Date: July 2010
Arms Assigned Interventions
Experimental: 001
JNJ-41443532 25mg tablet once daily
Drug: JNJ-41443532
25mg tablet once daily
Experimental: 002
JNJ-41443532 100mg tablet once daily
Drug: JNJ-41443532
100mg tablet once daily
Experimental: 003
JNJ-41443532 250mg tablet once daily
Drug: JNJ-41443532
250mg tablet once daily
Experimental: 004
JNJ-41443532 500mg once daily (with 250mg tablets)
Drug: JNJ-41443532
500mg once daily (with 250mg tablets)
Experimental: 005
JNJ-41443532 1000mg once daily (with 250mg tablets)
Drug: JNJ-41443532
1000mg once daily (with 250mg tablets)
Experimental: 006
JNJ-41443532 1500mg once daily (with 250mg tablets)
Drug: JNJ-41443532
1500mg once daily (with 250mg tablets)
Placebo Comparator: 007
Placebo Matching placebo
Drug: Placebo
Matching placebo

Detailed Description:

This is a randomized (study drug assigned by chance), double-blind (neither physician nor participant knows the name of the assigned drug), placebo-controlled, single and multiple ascending dose study conducted at a single study center. The study has 4 parts. Part 1 is a randomized, double-blind, alternating panel, single ascending oral dose study. Two alternating treatment panels (A and B) each with nine healthy male participants will be studied with successively increasing dose levels. Part 2 is a randomized, open-label (all people involved know the identity of the intervention), 2-period crossover study to evaluate what the effect of administering JNJ- 41443532 with food (i.e. standard high fat breakfast meal) relative to administration in the fasted state will have on pharmacokinetics/blood levels of JNJ-41443532. Part 3 is a randomized, double-blind, single oral dose study in obese, otherwise healthy male participants. Part 4 is a double-blind, randomized, placebo-controlled multiple ascending dose study in up to 5 sequential treatment groups of healthy male participants. Safety assessments include monitoring of adverse events, and evaluation of lab results, cardiac parameters, vital signs, and physical exams. In Parts 1, 2, and 3 participants receive study medication (JNJ-41443532 or placebo) orally on Day 1 after an overnight fast of at least 10 hours; planned doses are 25 to 1500 mg. In Part 4, participants receive study medication (JNJ-41443532 or placebo) orally each day for 10 consecutive days after an overnight fast of at least 10 hours; planned doses are 100 to 1000 mg.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males, age 18 to 45 years inclusive for Part 1 and age 18 to 55 years inclusive for Parts 2, 3, and 4
  • Weight = 60 kilograms and Body Mass Index (BMI) between 18.5 and 29.9 kg/m2 (inclusive)
  • BMI between 30 to 39.9 kg/m2 for obese participants
  • Healthy on the basis of physical examination, medical history, vital signs, electrocardiogram (ECG), and clinical laboratory tests performed at screening
  • Men must agree to use a double barrier method of birth control (e.g. condom and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) and to not donate sperm during the study and for 3 months after receiving the last dose of study drug
  • Willing to adhere to the prohibitions and restrictions specified in this protocol

Exclusion Criteria:

  • History of, or currently active, significant illness or medical disorders, including (but not limited to) cardiovascular disease (including cardiac arrhythmias, myocardial infarction, stroke, peripheral vascular disease), endocrine or metabolic disease (e.g. hyper/hypo-thyroidism), hematological disease (e.g. von Willebrand's disease or other bleeding disorders), respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmologic disorders (including retinal disorders or cataracts), neoplastic disease, skin disorder, or any other illness that the Investigator considers should exclude the participant
  • Participants at risk for QTc prolongation (specific heart rhythm irregularity)
  • Within 12 months prior to screening, has had a clinically important, serious infection (e.g. hepatitis, pneumonia, or pyelonephritis), has been hospitalized for an infection or has been treated with intravenous (IV) antibiotics for an infection
  • Smoker or tobacco user within the past 3 months
  • History of alcohol or drug abuse
  • History of clinically significant drug and/or food allergies, including allergies or intolerance (e.g. lactose intolerance)
  • Donation of 1 or more units of blood or acute loss of an equivalent amount of blood within 60 days prior to study drug administration
  • Received an experimental drug or used an experimental medical device within 60 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01106469

Locations
Belgium
Merksem, Belgium
Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

No publications provided

Responsible Party: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier: NCT01106469     History of Changes
Other Study ID Numbers: CR017065, 41443532EDI1001
Study First Received: April 15, 2010
Last Updated: April 7, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
Healthy Volunteers
Healthy
JNJ-41443532
Pharmacokinetics

ClinicalTrials.gov processed this record on November 25, 2014